Mild CMV Esophagitis: When Valganciclovir Has Not Resolved Symptoms
This protocol applies to patients with mild cytomegalovirus (CMV) esophagitis in whom initial oral therapy with valganciclovir has not achieved the expected clinical response. The goal at every line remains the same — but when the first approach falls short, a structured next-line plan is needed.
Previous Line — Failure Condition
First-line therapy for mild CMV esophagitis is valganciclovir, with a target of complete resolution of signs and symptoms within 21–42 days. When that target is not reached, this protocol provides the next step.
Next-Line Approach (Partial Overview)
After valganciclovir failure in mild CMV esophagitis, the protocol moves to alternative intravenous antiviral agents. Multiple options are outlined, each with distinct administration requirements. The complete regimen, sequencing, and full administration guidance are available in the structured protocol.
Treatment Goal
Resolution of signs and symptoms of CMV esophagitis within 21–42 days.
References
- Valganciclovir 900 mg PO every 12 hours can be used in patients with mild disease (AIII).
- Oral valganciclovir can be used in patients with mild disease (AIII).
- Foscarnet 60 mg/kg IV every 8 hours or 90 mg/kg IV every 12 hours (BIII)—for patients with treatment-limiting toxicities to ganciclovir or with ganciclovir resistance; or
- Cidofovir 5 mg/kg/week IV for 2 weeks, then 5 mg/kg IV every other week.
- Administer 1 L of normal saline before and, if additional fluid load can be tolerated, administer another 1 L of normal saline after cidofovir infusion.
- Administer probenecid 2 g PO 3 hours before each cidofovir dose followed by 1 g PO 2 hours after the dose and 1 g PO 8 hours after the dose (total of 4 g) (CI).
- 21–42 days or until signs and symptoms have resolved (AIII).
View source ↗